FT.com / Search

1-10 of 68,009 results for GW Equity LLC

Sorry, we found no matches with all of your words. Here are the nearest matches with some of the words.

FT Suggests - Try these pages on FT.com

Sort by:

Relevance
Date

10:43pm
Buy-out groups eye Kabel Deutschland
...International and Bain Capital, the US private equity groups, are each thought to have submitted separate...Kabel Deutschland, which is owned by Providence Equity Partners, the US private equity group.Bankers say they are prepared to provide... By Martin Arnold in Berlin
February 25, 2009
Positive Sativex study sends GW shares higher
Shares in GW Pharmaceuticals, the developer of an experimental...due to report next month. Stephen Wright, GW’s research and development director, said...point” would come with the findings of GW’s larger study, which could pave the way... By Andrew Jack
March 11, 2009
GW Pharma boosted by Sativex advance
Shares in GW Pharmaceuticals jumped more than 40 per cent...second quarter of this calendar year.” GW declined to say when the drug was likely to...achieved there could be more upside.” GW said that it had amended the terms of its... By John O’Doherty
May 20, 2009
GW Pharma seeks Sativex approval
...as early as this time next year, after GW Pharmaceuticals filed for approval of its Sativex...for the business,” said Justin Gover, GW managing director. “We are anticipating...our business from next year onwards.” GW makes Sativex using two strains of cannabis... By John O’Doherty in London
8:23am
Hargreaves Lansdown pays special dividend
...assets under management was mainly due to the sharp rise in equity markets during the period, with the the FTSE All-Share index...client money.The company said clients had edged back into equity investments during the period, with stocks now accounting for... By Patrick Jenkins, Banking Editor
February 25, 2009
Positive Sativex study sends GW shares higher
Shares in GW Pharmaceuticals, the developer of an experimental...due to report next month. Stephen Wright, GW's research and development director, said...inflexion point" would come with the findings of GW's larger study, which could pave the way... By Andrew Jack
March 12, 2009
MS drug lifts GW Pharma
GW Pharmaceuticals rose 50 per cent to 59¾p on...spasticity in patients with multiple sclerosis. GW said it would now seek approval from European...approval process should be fairly quick and GW should see the result of its application within... By Neil Hume and Bryce Elder
January 23, 2008
Licensing agreement narrows GW’s loss
GW Pharmaceuticals narrowed losses on the back of...analyst at company broker Investec, said GW was in a strong position for 2008 with “good...regulatory approvals starting to come through”. GW also said it had recorded “highly promising... By Salamander Davoudi
April 9, 2008
GW hurt by Sativex trial
GW Pharmaceuticals became the latest casualty in...time round," he said. But Ibraheem Mahmood, GW's broker at Investec, was more bullish, saying...FT Comment * This is a painful moment for GW; the market was expecting positive results... By Salamander Davoudi
January 4, 2006
GW to begin US imports of cannabis-based drug
GW Pharmaceuticals will this year begin what are...cancer. Justin Gover, managing director of GW, said that the group had not encountered any...biotechnology analyst at Canaccord, said that given GW’s previous history of over-promising and under... By Lisa Urquhart in London